A Phase 2A, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study to Evaluate The Efficacy And Safety Of Oral PF-06651600 AND Pf-06700841 As Induction And Open Label Extension Treatment In Subjects With Moderate To Severe Crohn’s Disease